PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
|
Pre-Market Last Trade |
Last $ 0.30 ▲ 0.00 (0.51%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.2935 | 0.00 | 0.00 | 0.00 | 0.2935 | 06:49:16 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.30 | 0.3071 | 0.0071 | 2.31% | - | - |
| Stock Trades | Traded Volume | Average Volume | 52 Week Range |
|---|---|---|---|
| 7 | 10,217 | 12,227,946 | 0.1027 - 5.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:49:16 | 1 | $ 0.2992 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 11.28M | 38.45M | $ -20.57M | -7.93 | - | 36.94M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 15.00 | 3.90% |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/10/2019 | 15:07 | GlobeNewswire Inc. | Onconova Therapeutics, Inc. Announces Closing of $5.0.. |
| 12/10/2019 | 11:20 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/10/2019 | 08:02 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 12/09/2019 | 09:08 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/09/2019 | 09:00 | GlobeNewswire Inc. | Onconova Therapeutics Announces Data on Genomic Profiles of.. |
| 12/09/2019 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics, Inc. Announces $5.0 Million.. |
| 12/06/2019 | 16:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.30 | 0.505 | 0.2551 | 0.3311381 | 24,650,906 | -0.0065 | -2.17% |
| 1 Month | 0.35 | 0.77 | 0.1027 | 0.2638248 | 23,084,485 | -0.0565 | -16.14% |
| 3 Months | 1.75 | 1.86 | 0.1027 | 0.2900336 | 7,520,730 | -1.46 | -83.23% |
| 6 Months | 3.42 | 4.00 | 0.1027 | 0.3159698 | 3,610,263 | -3.13 | -91.42% |
| 1 Year | 3.33 | 5.25 | 0.1027 | 0.3874991 | 1,895,556 | -3.04 | -91.19% |
| 3 Years | 37.05 | 58.20 | 0.1027 | 4.81 | 1,007,269 | -36.76 | -99.21% |
| 5 Years | 58.50 | 122.55 | 0.1027 | 7.31 | 668,926 | -58.21 | -99.5% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways. |
